Myocarditis Not Recovered in 80% at 6 Months after Vaccination

Every cardiology office in America should be recognizing COVID-19 vaccine-induced myocarditis presenting in young persons

90 percent are male, with chest pain, effort intolerance, arrhythmias, and cardiac arrest after injections of mRNA vaccines.

As I see these patients, the common question is “when is this over?”.

While ECG and blood tests tend to normalize quickly, my concern is that ongoing inflammation is occurring due to continued production of Wuhan Spike protein coded by the long lasting Pfizer or Moderna mRNA vaccines.

While blood tests can give inferences on inflammation, cardiologists also use cardiac magnetic resonance imaging (MRI) to visualize the inflammation, establish the diagnosis, and craft a prognosis. We would hope young teenagers would resolve their MRI results and go on with life. A recent report to the contrary caught my attention.

Barmada et al studied a clinical cohort consists of 23 patients hospitalized for vaccine-associated myocarditis and/or pericarditis. The cohort was predominately male (87 percent) with an average age of 16.9 ± 2.2 years (ranging from 13 to 21 years).

Patients had largely noncontributory past medical histories and were generally healthy before vaccination. Most patients had symptom onset 1 to 4 days after the second dose of the BNT162b2 mRNA vaccine.

Six patients either first experienced symptoms after a delay of >7 days after vaccination or were incidentally positive for SARS-CoV-2 by polymerase chain reaction (PCR) testing upon hospital admission; these six patients were thus excluded from further analyses, although they potentially reflect the breadth of clinical presentations of vaccine-associated myopericarditis.

The remaining cohort of 17 patients showed no evidence of recent prior SARS-CoV-2 infection, with antibodies to spike (S) protein but not to nucleocapsid (N) protein and negative nasopharyngeal swab reverse transcription quantitative PCR at hospital admission.

Barmada A, Klein J, Ramaswamy A, Brodsky NN, Jaycox JR, Sheikha H, Jones KM, Habet V, Campbell M, Sumida TS, Kontorovich A, Bogunovic D, Oliveira CR, Steele J, Hall EK, Pena-Hernandez M, Monteiro V, Lucas C, Ring AM, Omer SB, Iwasaki A, Yildirim I, Lucas CL. Cytokinopathy with aberrant cytotoxic lymphocytes and profibrotic myeloid response in SARS-CoV-2 mRNA vaccine-associated myocarditis. Sci Immunol. 2023 May 12;8(83):eadh3455. doi: 10.1126/sciimmunol.adh3455. Epub 2023 May 5. PMID: 37146127.

While the authors clearly show high levels of inflammatory markers, my attention was drawn to the follow-up MRI scans.

As shown in the figure, only 20 percent had resolved their abnormalities (late gadolinium enhancement) at over six months (199 days). This paper raises questions:

1) is there ongoing heart damage and inflammation at six months?

2) does the LGE in 80 percent represent a permanent “scar” putting these children at risk for future cardiac arrest?

These data strongly call for large scale research into this emerging problem given the large number of potential young persons at risk.

See more here substack.com

Please Donate Below To Support Our Ongoing Work To Expose The Lies About Covid 19

PRINCIPIA SCIENTIFIC INTERNATIONAL, legally registered in the UK as a company incorporated for charitable purposes. Head Office: 27 Old Gloucester Street, London WC1N 3AX. 

Trackback from your site.

Comments (2)

  • Avatar

    Tom

    |

    So many questions and no answers. I expect most cardiologists will want to do catheterizations and stent procedures along with adding several heart related drugs. Of course, this will not address the real problem. But your doc will be able to get a bigger boat and a bigger RV…and in this day and age, that is ALL that matters.

    Reply

  • Avatar

    VOWG

    |

    “They” will refuse to recognize it because if they do they are admitting culpability to the poisoning of millions of people.

    Reply

Leave a comment

Save my name, email, and website in this browser for the next time I comment.
Share via